Prothena | PRTA - Equity Capital And Reserves


Prothena reported $294.99M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Akebia Therapeutics USD 41.59M 12.37M Sep/2025
ALKERMES USD 1.82B 85.86M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Exelixis USD 2.16B 619K Dec/2025
Immunic USD 10.5M 23.41M Sep/2025
Incyte USD 5.17B 516.28M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
MacroGenics USD 67M 20.38M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Prothena USD 294.99M 29.34M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025
Xoma USD 87.94M 15.5M Sep/2025